SCHEMBL2174512

SCHEMBL2174512

COc1cc(Br)c(C(OC)OC)cc1OC

nearest known ligand 0.49

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
GAA P10253 2/20 0.44
PRKDC P78527 1/20 0.44
POLB P06746 1/20 0.43
L3MBTL1 Q9Y468 1/20 0.43
LCK P06239 1/20 0.42
FYN P06241 1/20 0.42
CYP1A2 P05177 2/20 0.42
CYP3A4 P08684 2/20 0.42
CYP2C9 P11712 2/20 0.42
CYP2C19 P33261 2/20 0.42
MGAM O43451 1/20 0.41
SI P14410 1/20 0.41
MGAM2 Q2M2H8 1/20 0.41
MAPT P10636 1/20 0.41
NPSR1 Q6W5P4 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7746122 0.89 LMNA (0.45) GAAMAPT
SCHEMBL7746175 0.89 LMNA (0.45) GAAMAPT
SCHEMBL5582119 0.84 P2RX3 (0.35) GAAPOLBL3MBTL1CYP1A2CYP3A4
SCHEMBL7297079 0.82 LMNA (0.49) POLBL3MBTL1CYP3A4MAPT
SCHEMBL7281047 0.80 CYP1A2 (0.46) GAAPRKDCPOLBL3MBTL1LCK
SCHEMBL7383152 0.80 MEN1 (0.50) L3MBTL1MAPT
Ammonia Solution, Strong SCHEMBL27836692 0.78 CYP1A2 (0.45) GAAPRKDCPOLBL3MBTL1LCK
SCHEMBL27795531 0.78 CYP1A2 (0.45) GAAPRKDCPOLBL3MBTL1LCK
SCHEMBL27937247 0.77 LCK (0.47) GAAPRKDCLCKFYNCYP1A2
SCHEMBL24456201 0.77 GAA (0.48) GAAPRKDCPOLBL3MBTL1LCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2868659-B1 Method for producing optically active naphthalene compound MITSUBISHI TANABE PHARMA CORP (JP) 2016-05-04 EP disclosed
EP-1964925-B1 PROCESS FOR PRODUCTION OF OPTICALLY ACTIVE 4-HYDROXY-1,2,3,4 -TETRAHYDROQUINOLINES MITSUBISHI TANABE PHARMA CORP (JP) 2016-03-30 EP disclosed
US-9181217-B2 Method for producing optically active naphthalene compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-11-10 US disclosed
US-20150152082-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2015-06-04 US disclosed
EP-2749558-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2014-07-02 EP disclosed
US-8754221-B2 Optically active cyclic alcohol compound and method for preparing the same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2014-06-17 US disclosed
US-20130237708-A1 Optically Active Cyclic Alcohol Compound And Method For Preparing The Same MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-09-12 US disclosed
EP-2371820-B1 Optically active cyclic alcohol compound and method for preparing the same MITSUBISHI TANABE PHARMA CORP (JP) 2013-08-28 EP disclosed
US-8471028-B2 Optically active cyclic alcohol compound MITSUBISHI TANABE PHARMA CORPORATION (JP) 2013-06-25 US disclosed
EP-1944291-B1 Optically active cyclic alcohol compound and method for producing same MITSUBISHI TANABE PHARMA CORP (JP) 2012-06-13 EP disclosed
EP-0748805-B1 Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them TANABE SEIYAKU CO (JP) 1998-04-08 EP disclosed
EP-0748805-A1 Naphthalene derivatives, process for the preparation thereof, and intermediates therefor, and pharmaceutical compositions comprising them TANABE SEIYAKU CO., LTD. (JP) 1996-12-18 EP disclosed
EP-0557016-B1 Naphthalene derivatives, processes for preparing the same, and synthetic intermediates therefor TANABE SEIYAKU CO (JP) 1996-06-19 EP disclosed
US-5342941-A Bronchodilating agents TANABE SEIYAKU CO., LTD. (JP) 1994-08-30 US disclosed
EP-0401125-B1 Biphenyl derivatives, process for preparing the same and intermediates therefor TANABE SEIYAKU CO (JP) 1994-08-24 EP disclosed
EP-0557016-A1 Naphthalene derivatives, processes for preparing the same, and synthetic intermediates therefor TANABE SEIYAKU CO., LTD. (JP) 1993-08-25 EP disclosed
US-5233057-A For treatment or prophylaxis of liver disorders TANABE SEIYAKU CO., LTD. (JP) 1993-08-03 US disclosed
US-5182404-A Liver disorders TANABE SEIYAKE CO., LTD. (JP) 1993-01-26 US disclosed
US-5103023-A Carboxy derivates with oxy subsitituents for treating liuer disorders TANABE SEIYAKU CO., LTD. (JP) 1992-04-07 US disclosed
EP-0401125-A2 Biphenyl derivatives, process for preparing the same and intermediates therefor TANABE SEIYAKU CO., LTD. (JP) 1990-12-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150152082-A1 METHOD FOR PRODUCING OPTICALLY ACTIVE NAPHTHALENE COMPOUND HRH1, HRH4, RB1 GAA 2968/4885PRKDC 251/4885POLB 494/4885
US-20130237708-A1 Optically Active Cyclic Alcohol Compound And Method For Preparing The Same ADH1C, ADH1A, ADH5 GAA 3418/4885PRKDC 1741/4885POLB 777/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.